CN115536772A - 一种甘油三酯分子印迹聚合物及其制备方法和应用 - Google Patents
一种甘油三酯分子印迹聚合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN115536772A CN115536772A CN202211210175.6A CN202211210175A CN115536772A CN 115536772 A CN115536772 A CN 115536772A CN 202211210175 A CN202211210175 A CN 202211210175A CN 115536772 A CN115536772 A CN 115536772A
- Authority
- CN
- China
- Prior art keywords
- triglyceride
- molecularly imprinted
- imprinted polymer
- surface carrier
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 title claims abstract description 88
- 229920000344 molecularly imprinted polymer Polymers 0.000 title claims abstract description 73
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 20
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 239000000178 monomer Substances 0.000 claims description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 14
- 229910004298 SiO 2 Inorganic materials 0.000 claims description 13
- 239000007810 chemical reaction solvent Substances 0.000 claims description 11
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 239000003480 eluent Substances 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- SJECZPVISLOESU-UHFFFAOYSA-N 3-trimethoxysilylpropan-1-amine Chemical compound CO[Si](OC)(OC)CCCN SJECZPVISLOESU-UHFFFAOYSA-N 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 4
- 239000003431 cross linking reagent Substances 0.000 claims description 4
- 239000003999 initiator Substances 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 238000001132 ultrasonic dispersion Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000000975 co-precipitation Methods 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 claims 3
- 238000001035 drying Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 abstract description 23
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 abstract description 4
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 abstract description 4
- 230000000295 complement effect Effects 0.000 abstract description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 24
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 239000000243 solution Substances 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 125000002133 (4-hydroxy-3-iodo-5-nitrophenyl)acetyl group Chemical group OC1=C(C=C(C=C1I)CC(=O)*)[N+](=O)[O-] 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000019280 Pancreatic lipases Human genes 0.000 description 3
- 108050006759 Pancreatic lipases Proteins 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229940116369 pancreatic lipase Drugs 0.000 description 3
- 239000002861 polymer material Substances 0.000 description 3
- 239000003361 porogen Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000007127 saponification reaction Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 2
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000011246 composite particle Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- SLZAMKNXRDJWLA-UHFFFAOYSA-N 1-(5-acetyl-2,6-dimethyl-1,4-dihydropyridin-3-yl)ethanone Chemical compound CC(=O)C1=C(C)NC(C)=C(C(C)=O)C1 SLZAMKNXRDJWLA-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010041969 Steatorrhoea Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000010560 atom transfer radical polymerization reaction Methods 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000696 magnetic material Substances 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000013214 routine measurement Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000005476 size effect Effects 0.000 description 1
- 208000001162 steatorrhea Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
- C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F220/04—Acids; Metal salts or ammonium salts thereof
- C08F220/06—Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/22—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
- B01J20/26—Synthetic macromolecular compounds
- B01J20/268—Polymers created by use of a template, e.g. molecularly imprinted polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F222/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical and containing at least one other carboxyl radical in the molecule; Salts, anhydrides, esters, amides, imides, or nitriles thereof
- C08F222/10—Esters
- C08F222/1006—Esters of polyhydric alcohols or polyhydric phenols
- C08F222/102—Esters of polyhydric alcohols or polyhydric phenols of dialcohols, e.g. ethylene glycol di(meth)acrylate or 1,4-butanediol dimethacrylate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/26—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a solid phase from a macromolecular composition or article, e.g. leaching out
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2333/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers
- C08J2333/02—Homopolymers or copolymers of acids; Metal or ammonium salts thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2335/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a carboxyl radical, and containing at least one other carboxyl radical in the molecule, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Derivatives of such polymers
- C08J2335/02—Characterised by the use of homopolymers or copolymers of esters
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Abstract
本发明第一方面提出一种甘油三酯分子印迹聚合物,其以甘油三酯为模板分子制备,并且具有甘油三酯识别位点以吸附甘油三酯,该位点在三维印迹空腔的大小、形状和功能上均与甘油三酯互补,具有良好的特异性,能够对甘油三酯产生快速高效的特异性吸附。进一步地,甘油三酯分子印迹聚合物还包括表面载体四氧化三铁,具有良好生物相容性。本发明第二方面提出一种甘油三酯分子印迹聚合物的制备方法。本发明第三方面提出甘油三酯分子印迹聚合物在制备用于吸附或降低人体内甘油三酯含量、减缓高脂血症或减轻体重的产品中的应用。
Description
技术领域
本发明属于高分子聚合物材料技术领域,具体涉及一种甘油三酯分子印迹聚合物及其制备方法和应用。
背景技术
血脂是血浆中的中性脂肪(甘油三酯)和类脂(磷脂、糖脂、固醇、类固醇)的总称,广泛存在于人体中,它们是生命细胞的基础代谢必需物质。一般说来,血脂中的主要成分是甘油三酯和胆固醇,其中甘油三酯(TG)是长链脂肪酸和甘油形成的脂肪分子,是人体内含量最多的脂类。血清甘油三酯是所有脂蛋白中的甘油三酯总和,临床上作为一项重要的血脂常规测定指标,与总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇共同作为血脂测定的基本项目。TG主要存在于乳糜微粒、极低密度脂蛋白(VLDL)及其残粒,残粒可侵入血管内皮下,后经脂蛋白酯酶(LPL)降解后的产物促进泡沫细胞生成,进而导致动脉粥样硬化加速。高脂血症所引起的动脉粥样硬化是造成冠心病、高血压和脑血管疾病的主要原因,全球每年约有1200万人死于心血管病和脑中风。所以,高脂血症的预防与治疗非常重要,这已引起全人类的高度关注。
甘油三酯处于临界高水平和高水平的患者,常常伴有复合型高脂血症和糖尿病性脂质紊乱血症,与冠心病死亡和心血管疾病(心绞痛、心肌梗死)直接相关,因此,降低血清甘油三酯(TG)水平已经成为心脑血管疾病防治中不可或缺的一个方面。目前用于治疗高脂血症的化学药起效快且疗效确切,但是化学药都有不同程度的毒副作用,如阿托伐他汀的常见不良反应为消化道反应、肝功能异常和肌痛,其发生多见于接受高剂量和长期治疗的患者。
对于与高血脂相关的肥胖病症的预防与治疗,目前市场上的减肥药物主要为胰脂肪酶抑制剂和作用于中枢神经系统的食欲抑制剂两类。胰脂肪酶抑制剂奥利司他通过抑制胰脂肪酶活性,进而抑制食物中脂肪的分解吸收而减肥,但其会引起脂肪泻,可造成脂溶性维生素缺乏,最近还有报道其可引起肝功能损害。食欲抑制剂由于可引起神经系统不良反应,存在大脑中枢和心血管系统等方面的安全风险。
发明内容
针对上述问题,本发明第一方面提出一种甘油三酯分子印迹聚合物,其以甘油三酯为模板分子制备,并且具有甘油三酯识别位点以吸附甘油三酯。
上述方案以甘油三酯为模板,制备具有特异识别空腔的甘油三酯分子印迹聚合物,从而在聚合物结构中获得高选择性的识别位点,该位点在三维印迹空腔的大小、形状和功能上均与甘油三酯互补,具有良好的特异性,能够对甘油三酯产生快速高效的特异性吸附。
优选地,甘油三酯分子印迹聚合物还包括功能单体甲基丙烯酸。
优选地,甘油三酯分子印迹聚合物还包括表面载体四氧化三铁,Fe3O4磁性纳米微粒具有小尺寸效应、良好的靶向性、生物相容性和超顺磁性,因此,以磁性四氧化三铁为表面载体制备的甘油三酯分子印迹聚合物,具有良好生物相容性,且能够形成较多的吸附位点,吸附效率高。
本发明第二方面提出一种甘油三酯分子印迹聚合物的制备方法,其包括以下步骤:
S1,将模板分子甘油三酯溶于反应溶剂,并加入功能单体预聚合,获得溶液A;
S2,向所述溶液A中加入表面载体和功能试剂,反应后获得产物B;
S3,将所述产物B中的模板分子洗脱后干燥,获得产物甘油三酯分子印迹聚合物。
进一步地,表面载体为四氧化三铁,S2还包括对表面载体进行二氧化硅包覆和氨基改性处理。二氧化硅包覆使磁性复合粒子具有高稳定性、抗氧化性和生物相容性,氨基改性能够提高其疏水性,同时有利于在其表面合成甘油三酯分子印迹聚合物。
进一步地,上述表面载体的制备包括以下步骤:
S21,通过化学共沉淀法合成Fe3O4;
S22,通过Stober方法合成Fe3O4@SiO2;
S23,将所述Fe3O4@SiO2与乙醇和3-氨丙基三甲氧基硅烷反应,获得产物磁性表面载体。
优选地,S1中的反应溶剂采用氯仿。以氯仿为反应溶剂制备的甘油三酯分子印迹聚合物对甘油三酯具有较佳的吸附效果。
优选地,S1中功能单体为甲基丙烯酸(MAA),模板分子甘油三酯和功能单体甲基丙烯酸的摩尔比为1:6,以该比例制备的甘油三酯分子印迹聚合物对甘油三酯具有较佳的吸附效果。
优选地,
S1具体包括,将模板分子甘油三酯溶于有机溶剂氯仿,加入功能单体,超声分散后在低温下预聚合;
S2具体包括,加入表面载体磁性四氧化三铁,超声分散后加入交联剂、引发剂和致孔剂,在高温无氧环境下反应;
S3具体包括,采用乙醇为洗脱剂洗脱,直至反应体系中检测不到甘油三酯。
本发明第三方面提出将采用上述任一甘油三酯分子印迹聚合物或上述任一方法制备的甘油三酯分子印迹聚合物在制备用于吸附或降低人体内甘油三酯含量、减缓高脂血症或减轻体重的产品中的应用。
本发明选取甘油三酯为模板,通过原子转移自由基聚合的方式,制备了可以捕获人体血浆中甘油三酯的分子印迹聚合物材料。该材料可以形成甘油三酯-分子印迹聚合物的复合物并从体内排出,因此可以将该分子印迹材料应用于减缓高甘油三酯血症以及瘦身减肥相关产品中。与现有降血脂药物相比,本发明所制备的甘油三酯分子印迹聚合物材料,具有高选择性与强特异性的吸附作用,可以实现体内甘油三酯高效快速的降低。
附图说明
附图帮助进一步理解本申请。为了便于描述,附图中仅示出了与有关发明相关的部分。
图1为一实施例中甘油三酯分子印迹聚合物的制备流程图;
图2为一实施例中以Fe3O4@SiO2-NH2为表面载体的磁性甘油三酯分子印迹聚合物MIPs的制备过程示意图;
图3为一实施例中甘油三酯分子印迹聚合物对不同浓度甘油三酯的吸附效果分析;
图4为一实施例中磁性甘油三酯分子印迹聚合物的生物相容性及吸附能力评估;
图5为一实施例中磁性甘油三酯分子印迹聚合物的形态表征。
具体实施方式
下面结合附图和实施例对本申请作进一步的详细说明。此处所描述的具体实施例仅用于解释相关发明,而非对该发明的限定。在不冲突的情况下,本申请中的实施例及实施例中的特征可以相互组合。
图1为一实施例甘油三酯分子印迹聚合物的制备流程图,其包括步骤:
S1,将模板分子甘油三酯溶于反应溶剂,并加入功能单体预聚合,获得溶液A;
S2,向所述溶液A中加入表面载体和功能试剂,反应后获得产物B;
S3,将所述产物B中的模板分子洗脱后干燥,获得产物甘油三酯分子印迹聚合物。
分子印迹技术(MIT)是以某特定分子为模板,制备对该特定分子具有特异选择性聚合物的过程,即制备该模板分子的分子印迹聚合物(MIPs)。上述方案以甘油三酯为模板分子制备MIPs,对甘油三酯具有很高的特异性识别和分离能力,可以将其从复杂体系中特异性的提取出来,具有特殊的选择识别能力。
在具体实施例中,甘油三酯分子印迹聚合物的制备包括步骤:
S1,取模板分子甘油三酯1mmol溶于20mL反应溶剂,加入功能单体甲基丙烯酸,4℃下预聚合12h,获得溶液A;
S2,向溶液A中加入0.2g表面载体,超声分散15min,再加入交联剂EGDMA 20mmol,引发剂AIBN 40mg,致孔剂ACN 40mL,通氮气15min后,置于65℃水浴中机械搅拌24h,获得产物B;
S3,以乙醇为洗脱剂,摇床震荡去除模板,直到洗脱液中检测不到甘油三酯为止,获得产物MIPs,用水清洗后干燥备用。
在具体实施例中,甘油三酯的检测采用化学测定法,即用碱水解(皂化)TG,以过碘酸氧化甘油生成甲醛,然后用显色反应测定甲醛。化学法化学测定法通常包括四个阶段:(1)TG的抽提分离;(2)皂化;(3)甘油糖的氧化;(4)氧化生成甲醛显色定量。
其中涉及的反应包括:
TG+KOH→3RCH2COOK+甘油
甘油+2HIO4→2HCHO+HCOOH
HCHO+2CH3COCH2COCH3+NH4+→3,5-二乙酰-1,4-二氢二甲基吡啶
试剂的配制方法包括:
皂化剂:称取6.0g KOH溶于60mL蒸馏水中,加异丙醇40mL混合,置棕色瓶中,室温避光保存;
氧化剂:称取7.7g无水醋酸铵溶于少量蒸馏水,加冰醋酸6mL,过碘酸0.1g,加蒸馏水定容到100mL,置棕色瓶中室温避光保存;
显色剂的配制:取0.4mL乙酰丙酮加异丙醇至100mL,置棕色瓶中室温避光保存;
测定过程包括:取干净试管2支,分别加入0.3mL的甘油三酯标准溶液和异丙醇溶液,再分别加入皂化剂1mL,立即充分摇匀,于65℃下水浴加热5min。各管依次加入氧化剂1mL及显色剂1mL,充分震荡混匀后65℃水浴加热15min,取出后冷却至室温,在420nm波长处测量其吸光度,以空白管校正零点,读取各管吸光度。
在具体实施例中,选取不同反应溶剂制备分子印迹聚合物MIPs,并对应地以相同方法但不加入模板分子制备非分子印迹聚合物NIPs,其对甘油三酯的吸附结果如下表,可见,在不同反应溶剂中制备的MIPs均对甘油三酯具有吸附作用,且氯仿为最佳反应溶剂。
表1不同反应溶剂中制备的MIPs对甘油三酯的吸附效果
在具体实施例中,以不同比例的模板分子和功能单体制备分子印迹聚合物MIPs。配制200μg/mL的标准甘油三酯溶液,取三份4mL标准溶液分别与功能单体合成分子印迹聚合物,其中模板分子与功能单体的摩尔比分别为1:4、1:6、1:8,并以对应地相同方法但不加入模板分子制备非分子印迹聚合物NIPs,在室温条件下充分进行吸附,其吸附结果如下表。可见,以不同比例的模板分子和功能单体制备的MIPs均对甘油三酯具有吸附作用,且1:6为最佳比例。
表2以不同模板分子与功能单体比例制备的MIPs对甘油三酯的吸附效果
在具体实施例中,以不同纳米材料为表面载体制备分子印迹聚合物MIPs,并对应地以相同方法但不加入模板分子制备非分子印迹聚合物NIPs,其对甘油三酯的吸附结果如下表。可见,以不同表面载体制备的聚合物均对甘油三酯具有吸附作用,且其中四氧化三铁为最佳载体。
表3以不同表面载体制备的MIPs对甘油三酯的吸附效果
进一步优选的实施例中,以Fe3O4@SiO2-NH2为表面载体制备具有生物安全性的磁性甘油三酯分子印迹聚合物MIPs。利用二氧化硅对Fe3O4纳米颗粒表面进行包覆,获得具有高稳定性、抗氧化性和生物相容性的磁性复合粒子,接着再对其进行氨基改性,以提高其疏水性,同时有利于在其表面合成甘油三酯分子印迹聚合物。图2为本实施例中以Fe3O4@SiO2-NH2为表面载体的磁性甘油三酯分子印迹聚合物MIPs的制备过程示意图。参见图2,具体包括:
1、化学共沉淀法合成Fe3O4:称取3.44g FeCl2·4H2O和9.35g FeCl3·6H2O,置于250mL三颈烧瓶内,加入150mL超纯水,快速搅拌下缓慢滴加20mL氨水(25%,v/v),90℃氮气氛围中反应1h,外磁场分离固体,用蒸馏水和无水乙醇反复洗涤沉淀物,水洗至中性,将沉淀物置于真空干燥箱中,75℃下干燥12h,获得磁性Fe3O4纳米颗粒;
2、依据Stober方法合成Fe3O4@SiO2:将0.5g Fe3O4粉末加入到60mL乙醇和水的混合溶液(体积比为5:1)中,超声20min,倾入三颈烧瓶中,采用磁力搅拌器搅拌,缓慢加入2mL氨水(25%,wt)和2mL正硅酸四乙酯(TEOS),30℃下搅拌6h,用外部磁铁分离固体和溶液,用1mol/L的盐酸溶液浸泡24h,水洗至中性,最后在60℃真空干燥箱内干燥12h,收集产物Fe3O4@SiO2;
3、合成Fe3O4@SiO2-NH2:称取0.4g Fe3O4@SiO2粉末,加入90mL乙醇和5mL 3-氨丙基三甲氧基硅烷(APS),用冰醋酸调节pH为4,在60℃下搅拌4h;分别用乙醇和氢离子水清洗三次,干燥收集固体;
4、制备MIPs-Fe3O4@SiO2:取模板分子甘油三酯1mmol溶于20mL氯仿,加入功能单体甲基丙烯酸MAA 6mmol,4℃下预聚合12h后,加入0.2g制备好的Fe3O4@SiO2-NH2,超声分散15min,再加入交联剂EGDMA 20mmol,引发剂AIBN 40mg,致孔剂ACN 40mL,通氮气15min。溶液置于65℃水浴中机械搅拌24h,反应结束后,以乙醇为洗脱剂,摇床震荡去除模板,直到洗脱液中检测不到甘油三酯为止,用水清洗MIPs,干燥备用。
图3为一实施例中制备的甘油三酯分子印迹聚合物对不同浓度甘油三酯的吸附效果分析,可见,本发明制备的聚合物能够有效吸附血浆中的甘油三酯,且随着甘油三酯浓度增加,吸附效果越好。
图4为一实施例中制备的磁性甘油三酯分子印迹聚合物的生物相容性及吸附能力评估。取3只相同周龄健康小白鼠,连续30天给药(0.2mg甘油三酯分子印迹聚合物/g体重),并进行称重,观察其体重变化。同时取3只相同周龄健康小白鼠,连续30天给药(0.2mg考来烯胺/g体重),并进行称重,观察其体重变化。参见图4,连续给药30天后,小鼠均存活,且生活状态良好,体重有轻微下降,可见,本实施例制备的甘油三酯磁性分子印迹聚合物具有生物安全性,与降血脂药物考来烯胺具有相同、甚至更好的降低体重的效果。
图5为一实施例中制备的磁性分子印迹聚合物的形态表征。扫描电镜对甘油三酯磁性分子印迹聚合物的形态表征说明该聚合物形状大小均一,粒径约为100nm,表面有孔隙且不平整,也即在磁性材料表面形成了较多的印迹位点。
本发明以甘油三酯分子印迹聚合物作为吸附剂,吸附剂内部具有特定大小及官能团的空腔作为甘油三酯的结合位点,能够快速吸附血液中的甘油三酯,随后排出体外。该甘油三酯磁性分子印迹聚合物选择性强,吸附效果好,副作用小,可作为药物组合物,用于预防和治疗与高血脂相关的疾病,如肥胖症、动脉硬化、高血脂、冠心病、糖尿病,以及其他一些心血管疾病;也可以用于减肥药物或保健品等产品中,帮助降低体重。
尽管结合优选实施方案具体展示和介绍了本申请的内容,但所属领域的技术人员应该明白,在不脱离所附权利要求书所限定的本申请的精神和范围内,没有做出创造性劳动的情况下,在形式上和细节上对本申请做出的各种变化,均为本申请的保护范围。
Claims (10)
1.一种甘油三酯分子印迹聚合物,其特征在于,所述甘油三酯分子印迹聚合物以甘油三酯为模板分子制备,并且具有甘油三酯识别位点以吸附甘油三酯。
2.根据权利要求1所述的甘油三酯分子印迹聚合物,其特征在于,所述甘油三酯分子印迹聚合物还包括功能单体甲基丙烯酸。
3.根据权利要求1所述的甘油三酯分子印迹聚合物,其特征在于,所述甘油三酯分子印迹聚合物还包括表面载体四氧化三铁。
4.一种甘油三酯分子印迹聚合物制备方法,其特征在于,包括以下步骤:
S1,将模板分子甘油三酯溶于反应溶剂,并加入功能单体预聚合,获得溶液A;
S2,向所述溶液A中加入表面载体和功能试剂,反应后获得产物B;
S3,将所述产物B中的模板分子洗脱后干燥,获得产物甘油三酯分子印迹聚合物。
5.根据权利要求4所述的甘油三酯分子印迹聚合物制备方法,其特征在于,所述表面载体包括四氧化三铁,S2还包括对表面载体进行二氧化硅包覆和氨基改性处理。
6.根据权利要求5所述的甘油三酯分子印迹聚合物制备方法,其特征在于,所述表面载体的制备包括以下步骤:
S21,通过化学共沉淀法合成Fe3O4;
S22,通过Stober方法合成Fe3O4@SiO2;
S23,将所述Fe3O4@SiO2与乙醇和3-氨丙基三甲氧基硅烷反应,获得产物磁性表面载体。
7.根据权利要求4所述的甘油三酯分子印迹聚合物制备方法,其特征在于,所述反应溶剂包括氯仿。
8.根据权利要求4所述的甘油三酯分子印迹聚合物制备方法,其特征在于,S1所述功能单体包括甲基丙烯酸,所述模板分子甘油三酯和功能单体甲基丙烯酸的摩尔比为1:6。
9.根据权利要求4所述的甘油三酯分子印迹聚合物制备方法,其特征在于,
S1具体包括,将模板分子甘油三酯溶于有机溶剂氯仿,加入功能单体,超声分散后在低温下预聚合;
S2具体包括,加入表面载体磁性四氧化三铁,超声分散后加入交联剂、引发剂和致孔剂,在高温无氧环境下反应;
S3具体包括,采用乙醇为洗脱剂洗脱,直至反应体系中检测不到甘油三酯。
10.根据权利要求1-3中任一项所述的甘油三酯分子印迹聚合物或根据权利要求4-9中任一项所述的方法制备的甘油三酯分子印迹聚合物在制备用于吸附或降低人体内甘油三酯含量、减缓高脂血症或减轻体重的产品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211210175.6A CN115536772B (zh) | 2022-09-30 | 2022-09-30 | 一种甘油三酯分子印迹聚合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211210175.6A CN115536772B (zh) | 2022-09-30 | 2022-09-30 | 一种甘油三酯分子印迹聚合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115536772A true CN115536772A (zh) | 2022-12-30 |
CN115536772B CN115536772B (zh) | 2023-12-22 |
Family
ID=84731842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211210175.6A Active CN115536772B (zh) | 2022-09-30 | 2022-09-30 | 一种甘油三酯分子印迹聚合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115536772B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118931980A (zh) * | 2024-08-16 | 2024-11-12 | 广州市浩立生物科技有限公司 | 一种以动物油脂为原料制备甘油二酯粉末的方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100210835A1 (en) * | 2009-02-18 | 2010-08-19 | Board Of Regents, The University Of Texas System | Mimetic Drug Delivery Systems for Release with Specific Molecular Triggers |
CN102417558A (zh) * | 2011-11-21 | 2012-04-18 | 嘉兴学院 | 一种分离莠去津的磁性分子印记聚合物及其制备方法 |
JP2012224591A (ja) * | 2011-04-21 | 2012-11-15 | Shuichi Kihata | 脂質吸収抑制物質 |
AU2020100965A4 (en) * | 2020-06-08 | 2020-08-20 | Animal Husbandry And Verterinary Research Institute Of Tibet Academy Of Agriculture And Animal Husbandry Sciences | Method For Preparation Of Solid Phase Extraction Column Of Sophocarpine Molecularly Imprinted Polymer |
-
2022
- 2022-09-30 CN CN202211210175.6A patent/CN115536772B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100210835A1 (en) * | 2009-02-18 | 2010-08-19 | Board Of Regents, The University Of Texas System | Mimetic Drug Delivery Systems for Release with Specific Molecular Triggers |
JP2012224591A (ja) * | 2011-04-21 | 2012-11-15 | Shuichi Kihata | 脂質吸収抑制物質 |
CN102417558A (zh) * | 2011-11-21 | 2012-04-18 | 嘉兴学院 | 一种分离莠去津的磁性分子印记聚合物及其制备方法 |
AU2020100965A4 (en) * | 2020-06-08 | 2020-08-20 | Animal Husbandry And Verterinary Research Institute Of Tibet Academy Of Agriculture And Animal Husbandry Sciences | Method For Preparation Of Solid Phase Extraction Column Of Sophocarpine Molecularly Imprinted Polymer |
Non-Patent Citations (1)
Title |
---|
XINYU CAO ET AL.,: "Synthesis and application of magnetic surface molecularly imprinted polymers in selective solid-phase extraction of epoxy triglyceride from deep frying oil", 《FOOD CONTROL》, vol. 137, pages 1 - 8 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118931980A (zh) * | 2024-08-16 | 2024-11-12 | 广州市浩立生物科技有限公司 | 一种以动物油脂为原料制备甘油二酯粉末的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN115536772B (zh) | 2023-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xu et al. | Dynamic polymer amphiphiles for efficient intracellular and in vivo protein delivery | |
Yavuz et al. | Synthesis of cholesterol imprinted polymeric particles | |
Hansson et al. | Grafting efficiency of synthetic polymers onto biomaterials: A comparative study of grafting-from versus grafting-to | |
Ciardelli et al. | Supported imprinted nanospheres for the selective recognition of cholesterol | |
Ghaemy et al. | Synthesis of chitosan networks: Swelling, drug release, and magnetically assisted BSA separation using Fe3O4 nanoparticles | |
CN113105614A (zh) | 一种易降解响应型可核心交联的两亲性嵌段聚合物及其制备方法和作为药物载体的应用 | |
CN115536772A (zh) | 一种甘油三酯分子印迹聚合物及其制备方法和应用 | |
Gan et al. | Effects of microsize on the biocompatibility of UiO67 from protein-adsorption behavior, hemocompatibility, and histological toxicity | |
Tajahmadi et al. | Adsorption behavior of a gd-based metal–organic framework toward the quercetin drug: effect of the activation condition | |
Xiao et al. | Novel controlled drug release system engineered with inclusion complexes based on carboxylic graphene | |
Zhang et al. | Synthesis of a magnetic micelle molecularly imprinted polymers to selective adsorption of rutin from Sophora japonica | |
CN102604118A (zh) | 聚乙二醇树枝状聚合物及其制备方法 | |
CN114796153B (zh) | 一种载药型可降解分子印迹聚合物纳米粒子的制备方法 | |
CN101024149A (zh) | 一种血浆脂质成份吸附分离聚合物多孔膜材料、制备及其应用 | |
CN109248668A (zh) | 用于血液体外循环去除ldl的吸附剂及其制备方法和灌流器 | |
CN116942837A (zh) | 一种新型纳米载体及其制备方法和应用 | |
CN113332966B (zh) | 一种大麻二酚特异性吸附磁性分子聚合物材料及其制备方法 | |
CN101885814B (zh) | 多孔硅胶硅表面熊去氧胆酸分子印迹聚合物及其制备和应用 | |
CN107474191A (zh) | 一种光响应型智能纳米开关及其制备方法与应用 | |
CN114875015A (zh) | 一种脂肪酶-聚合物偶联物的制备方法及其在结构脂质转酯化上的应用 | |
CN101116829A (zh) | 一种键联金属卟啉的纳米高分子磁性微球及其制备方法 | |
CN102585113B (zh) | 一种定向保护官能团的分子印迹聚合物的制备方法及应用 | |
Wang et al. | Synthesis of diacylglycerol‐terminated lipid–polymer conjugates: application to cell surface modification | |
CN115040661B (zh) | 靶向药物载体及其制备方法和应用 | |
CN110638810A (zh) | 中空磁性水飞蓟宾缓释载体及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |